BRCA1/RAD51C甲基化对高级别浆液性卵巢癌的预测价值——PAOLA-1/ENGOT-ov25 III期试验的辅助研究
该辅助研究基于PAOLA-1/ENGOT-ov25 III期前瞻性试验数据,分析519例新诊断高级别浆液性卵巢癌(HGSOC)患者中BRCA1和RAD51C甲基化作为同源重组修复缺陷(HRD)判定工具的价值。甲基化分析采用定量甲基化特异性PCR,并与HRD评分、无进展生存期(PFS)和总生存期(OS)进行关联。结果显示,BRCA1甲基化67例(12.9%),RAD51C甲基化25例(4.8%);甲基化样本多为HRD+且与BRCA1/2突变几乎互斥;在甲基化肿瘤患者中,贝伐珠单抗联合奥拉帕利维持治疗较单用贝伐珠单抗显著改善PFS1(HR=0.49,95%CI 0.29-0.83,P=0.008);定义为「all-HRD」(含甲基化)的患者显示OS获益(HR=0.59,95%CI 0.41-0.86,P=0.007)。结论认为BRCA1/RAD51C甲基化可预测新诊断HGSOC对奥拉帕利联合贝伐珠单抗维持治疗的应答,与突变检测并行可识别近85%的HRD+样本且成本较低。
要点
- 在新诊断HGSOC中,BRCA1甲基化占12.9%(67例),RAD51C甲基化占4.8%(25例)。
- 甲基化样本多为HRD+,且与BRCA1/2突变几乎互斥。
- 甲基化肿瘤患者接受贝伐珠单抗联合奥拉帕利维持治疗较单用贝伐珠单抗显著改善PFS1(HR=0.49,95%CI 0.29-0.83,P=0.008)。
核心结论
- 本研究证实BRCA1/RAD51C甲基化用于预测新诊断HGSOC对奥拉帕利联合贝伐珠单抗维持治疗应答具有可行性和临床价值。
- 与突变检测并行评估甲基化可以较低成本识别近85%的HRD+样本。
- 本研究提示甲基化检测可较容易地实施,以优化从奥拉帕利联合贝伐珠单抗维持治疗中获益的患者选择。
研究设计与样本
- 本研究为PAOLA-1/ENGOT-ov25 III期前瞻性试验的辅助研究,纳入新诊断HGSOC患者519例(n=519)。
- 采用定量甲基化特异性PCR分析BRCA1和RAD51C甲基化,并与HRD评分、PFS和OS进行关联分析。
主要发现
- BRCA1甲基化67例(12.9%),RAD51C甲基化25例(4.8%)。
- 81例HRD评分失败的样本中有13例为甲基化。
- 甲基化样本为HRD+,平均评分(95%CI)分别为65.9(62.7-69.1)和53.3(48.0-58.6),且与BRCA1&2突变几乎互斥。
- 甲基化肿瘤患者接受贝伐珠单抗联合奥拉帕利维持治疗较单用贝伐珠单抗,PFS1获益显著且独立于甲基化比例(HR=0.49,95%CI 0.29-0.83,P=0.008)。
- 定义为「all-HRD」(含甲基化)的患者显示OS获益(HR=0.59,95%CI 0.41-0.86,P=0.007)。
关键数值与推荐
- BRCA1甲基化67例(12.9%),RAD51C甲基化25例(4.8%)。
- 甲基化样本平均HRD评分(95%CI)分别为65.9(62.7-69.1)和53.3(48.0-58.6)。
- 甲基化肿瘤患者贝伐珠单抗联合奥拉帕利维持治疗对比单用贝伐珠单抗的PFS1:HR=0.49(95%CI 0.29-0.83,P=0.008)。
- 「all-HRD」(含甲基化)患者OS:HR=0.59(95%CI 0.41-0.86,P=0.007)。
- 与突变检测并行评估甲基化可识别近85%的HRD+样本。
临床怎么用
- 本研究提示甲基化检测可较容易地实施,以优化从奥拉帕利联合贝伐珠单抗维持治疗中获益的患者选择。
- 与突变检测并行评估BRCA1/RAD51C甲基化可以较低成本识别近85%的HRD+样本。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE AND BACKGROUND: In high-grade serous ovarian cancer (HGSOC) bevacizumab (bev)/olaparib (ola) maintenance was approved for patients with homologous recombination DNA repair deficiency (HRD+) tumors. Although different methods exist to score genomic instability, DNA quality, tumor cell content, and costs may impair our ability to identify patients that will benefit from treatment. PATIENTS AND METHOD: We analyzed BRCA1 and RAD51C methylation as an HRD determination tool in patients newly diagnosed of HGSOC (n = 519) based on data from the PAOLA-1/ENGOT-ov25 trial phase III prospective trial. Methylation was analyzed using quantitative methylation specific PCR, correlated to HRD scores, PFS and OS. RESULTS: 67 (12.9 %) were BRCA1 and 25 (4.8 %) were RAD51C methylated. Of the 81 samples with a failed HRD score, 13 were methylated. Methylated samples were HRD+ (mean score [95 % CI]; 65.9 [62.7-69.1] and 53.3 [48.0-58.6]) and almost mutually exclusive of BRCA1&2 mutations. A significant PFS1 benefit independently of methylation ratios was observed in patients with methylated tumors with bev-ola maintenance compared to bev alone (HR=0.49, 95 % CI 0.29-0.83, P = 0.008). An OS benefit was shown for patients defined as "all-HRD" (including methylation) (HR=0.59, 95 % CI 0.41-0.86, P = 0.007). CONCLUSIONS: This study confirms the feasibility and clinical value of BRCA1/RAD51C methylation for predicting response to ola-bev maintenance in newly diagnosed HGSOC. Assessment of methylation in parallel to mutation testing allowed the identification of nearly 85 % of HRD+ samples at low costs. This study suggests that methylation testing could be easily implemented to optimize the selection of patients that benefit from olaparib+bevacizumab maintenance.
引用
- Blons H, Abdelli J, Landman S, et al. Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial. Eur J Cancer. 2025. PMID: 40513287. doi:10.1016/j.ejca.2025.115534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。